Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference14 articles.
1. Beyzarov E, Chen Y, Julg R, Naim K, Shah J, Gregory WW, Ayoub A, Caubel P. Global safety database summary of COVID-19-related drug utilization-safety surveillance: a sponsor’s perspective. Drug Saf. 2021;44(1):95–105. https://doi.org/10.1007/s40264-020-01035-x.
2. Centers for Disease Control and Prevention. CDC coronavirus disease 2019 (COVID-19): people with certain medical conditions. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html#:~:text=Like%20adults%2C%20children%20with%20obesity,very%20sick%20from%20COVID%2D19. Accessed 18 Jul 2022.
3. Tan EH, Sena AG, Prats-Uribe A, et al. COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries. Rheumatology (Oxford). 2021;60(SI):SI37–50.
4. Pahalyants V, Murphy WS, Klebanov N, et al. Immunosuppressive biologics did not increase the risk of COVID-19 or subsequent mortality: a retrospective matched cohort study from Massachusetts. J Am Acad Dermatol. 2022;86(1):252–5. https://doi.org/10.1016/j.jaad.2021.08.065.
5. Andersen KM, Mehta HB, Palamuttam N, et al. Association between chronic use of immunosuppresive drugs and clinical outcomes from coronavirus disease 2019 (COVID-19) hospitalization: a retrospective cohort study in a large US health system. Clin Infect Dis. 2021;73(11):e4124–30.